arrow
P

Parastoo B. Dahi

Memorial Sloan Kettering Cancer Center
H指数:36
被引数:5,861

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT

第三方病毒特异性T细胞用于免疫缺陷宿主及准入障碍:ASTCT专家小组的综述与评论

2026-05-020
PRE
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations

TP53突变携带的髓系恶性肿瘤中,移植后干预和慢性移植物抗宿主病对生存的影响

2026-04-120
PRE
Characterization of TPO Receptor Agonists for the Management of Thrombocytopenia after CAR T-cell Therapy

TPO受体激动剂用于治疗CAR T细胞治疗后血小板减少症的特征

2026-02-030
PRE
CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

CD19 CAR T细胞疗法在原发性皮肤弥漫大B细胞淋巴瘤,腿型中的应用

2026-01-300
OAAI
Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma

二十年单机构数据揭示复发/难治性伯基特淋巴瘤的罕见长期生存者

2026-01-011
OA
Time-of-Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

CAR T细胞输注的昼夜时间与弥漫性大B细胞淋巴瘤的结局

Blood
IF23.1
2025-12-260
OAAI
Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study

CHARM是老年患者异基因移植后预测老年病发病率和毒性的指标:BMT CTN 1704研究

2025-11-240
OAAI
Incidence and outcomes of Adenovirus (ADV) infections after allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis.

腺病毒(ADV)感染在异基因造血细胞移植中使用移植后环磷酰胺(PTCy)为基础的移植物抗宿主病(GVHD)预防后的发生率及结局。

2025-11-210
PRE
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

CD19 CAR-T疗法后大B细胞淋巴瘤患者糖皮质激素使用模式与安全性

2025-11-010
OAAI
ANTIBODY TITERS OF VACCINE-PREVENTABLE PATHOGENS AT ONE YEAR POST CD19 CAR-T CELL THERAPY

疫苗可预防病原体的抗体滴度:CD19 CAR-T细胞治疗1年后

2025-11-010
PRE
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

CD19靶向CAR T细胞疗法在大型B细胞淋巴瘤中的比较真实世界结果

2025-08-190
OAAI
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

自体干细胞移植后,外周T细胞淋巴瘤的罗米地辛维持治疗

2025-04-070
OAAI
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704

新型复合健康评估风险模型用于老年异基因移植受者:BMT-CTN 1704

2025-03-200
OA
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines

美国老年评估实践:针对接受造血细胞移植或嵌合抗原受体T细胞治疗的老年人——移植与细胞治疗学会老年特别兴趣小组与实践指南委员会医师调查

2025-02-010
PRE